ArticleEuropean urology2023

Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.

Salil S Ghamande et al.PubMed ↗Publisher ↗

No numbers read from the abstract.